UK clinical trial updates to look out for in 2025
Results or further analyses are expected in 2025 from UK trials of terazosin, amantadine, dazucorilant and interleukin-2. The MND-SMART platform trial is also expected to continue recruiting, add drugs and open five new sites.
Why this matters
These updates may help researchers decide which treatments warrant larger or continued testing. They do not establish that any of these treatments works, and the expected results do not change treatment for people with MND now.
Limitations and context
This information comes from a March 2025 organisational blog, not from newly published trial results. Several updates are described as expected rather than available findings. The blog says the dazucorilant trial did not meet its primary endpoint, while the full analysis of the interleukin-2 trial was still pending. The article does not provide detailed participant numbers or full trial results for the expected analyses.